Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Phase 3

Completed

Conditions: Heterozygous Familial Hypercholesterolemia
ASCVD
Elevated Cholesterol
Homozygous Familial Hypercholesterolemia

Interventions: Drug: Inclisiran Sodium

First Posted Date: 2019-01-23

Last Posted Date: 2024-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3275

Registration Number: NCT03814187

Locations: 🇺🇸
Research Site 10001-014, Columbus, Ohio, United States
🇺🇸
Research Site 10001-088, Houston, Texas, United States
🇺🇸
Research Site 10001-091, Houston, Texas, United States

and more 235 locations

A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QAW039
Drug: Placebo

First Posted Date: 2019-01-18

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT03810183

Locations: 🇬🇧
Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Phase 3

Terminated

Conditions: Central Retinal Vein Occlusion

Interventions: Drug: Aflibercept 2 mg
Drug: Brolucizumab 6 mg
Other: Sham injection

First Posted Date: 2019-01-18

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 493

Registration Number: NCT03810313

Locations: 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

Phase 2

Completed

Conditions: Presbyopia

Interventions: Drug: Placebo
Drug: UNR844-Cl

First Posted Date: 2019-01-18

Last Posted Date: 2022-05-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 125

Registration Number: NCT03809611

Locations: 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Nidufexor
Other: Placebo
Drug: Standard of Care (SoC)

First Posted Date: 2019-01-15

Last Posted Date: 2022-08-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 83

Registration Number: NCT03804879

Locations: 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Phase 3

Terminated

Conditions: Branch Retinal Vein Occlusion

Interventions: Drug: Brolucizumab 6 mg
Drug: Aflibercept 2 mg
Other: Sham injection

First Posted Date: 2019-01-14

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 450

Registration Number: NCT03802630

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1

Completed

Conditions: Colorectal Cancer
Gastroesophageal Cancer
Renal Cell Carcinoma

Interventions: Drug: Gevokizumab
Drug: Bevacizumab
Drug: Ramucirumab
Drug: Cabozantinib
Drug: Modified FOLFOX6
Drug: FOLFIRI
Drug: Paclitaxel

First Posted Date: 2019-01-10

Last Posted Date: 2025-03-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 167

Registration Number: NCT03798626

Locations: 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸
WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2018-12-24

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 216

Registration Number: NCT03785405

Locations: 🇹🇷
Novartis Investigative Site, Konak-Izmir, Turkey
🇺🇸
Mayo Clinic - Rochester, Rochester, Minnesota, United States

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Phase 2

Terminated

Conditions: Liver Transplant Rejection

Interventions: Drug: Tacrolimus - MMF - corticosteroids
Biological: CFZ533

First Posted Date: 2018-12-19

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 129

Registration Number: NCT03781414

Locations: 🇺🇸
Wash U School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Duke Univ Medical Center, Durham, North Carolina, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

and more 7 locations

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

Phase 2

Completed

Conditions: Graft vs Host Disease

Interventions: Drug: INC424

First Posted Date: 2018-12-12

Last Posted Date: 2025-04-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT03774082

Locations: 🇹🇷
Novartis Investigative Site, Antalya, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy